Plan De Preparación Para La Pandemia De Influenza

Objectives

Provide a flexible global and national framework for anticipating, assessing and managing influenza-pandemic risk, recognising that pandemic onset, severity and spread cannot be predicted precisely and that plans must be adaptable to different viral and epidemiological scenarios.[1][2][3]The central objectives are to assess risks posed by newly detected influenza viruses, manage risks when a virus can transmit extensively and cause severe disease, reduce transmission and secondary disruption, and prevent avoidable public panic.[4]

• Establish national pandemic plans and National Pandemic Planning Committees, with national authorities holding primary responsibility for preparedness and risk management.[1][5]
• Detect, confirm and characterise novel influenza A viruses, including their sources, transmission patterns, genetic properties and susceptibility to available antiviral medicines.[6][7]
• Use graded preparedness levels before pandemic declaration and pandemic phases after sustained human-to-human transmission is confirmed, allowing proportionate precautionary action while avoiding unnecessary alarm.[8][9][10]
• Strengthen surveillance, laboratory capacity, scientific and medical consensus, pharmaceutical supply and logistics, legal and political preparedness, communications, and cross-sectoral coordination.[11][12]
• Support rapid development, testing, production and equitable distribution of pandemic vaccines, while preparing policies for antiviral medicines where these may be the only specific intervention against a novel virus.[9][13][14]
• Plan for multiple pandemic waves, later recovery, and post-pandemic assessment, returning to inter-pandemic arrangements when influenza activity normalises and immunity to the new subtype becomes widespread.[15][16]

Implementation

Deliver preparedness through complementary World Health Organization and national roles. The World Health Organization assesses novel-virus risks, defines preparedness levels and pandemic phases through its task force and international consultation, coordinates technical guidance and global information, and supports resource mobilisation for countries with limited capacity.[17][2][13]National authorities establish and activate pandemic plans, led by permanent National Pandemic Planning Committees with clear command arrangements and periodically reported progress.[5][18]

• Maintain coordinated surveillance across human and animal health, using National Influenza Centres as frontline laboratories and World Health Organization Collaborating Centres for reference testing, comparative analysis, reagent development, training and specialist research.[6][7][3]
• Escalate investigation at preparedness levels by excluding laboratory error, re-isolating and sequencing viruses, tracing exposures and contacts, testing antiviral sensitivity, applying case definitions, conducting serological studies, and investigating possible clusters outside the usual influenza season.[7][19]
• Coordinate public-health, veterinary, clinical, diagnostic, regulatory, scientific, pharmaceutical, emergency-response, communications, civil-society and community actors, supplemented by specialist expertise as required.[5][11][20]
• Develop scenario-based national contingencies for differing attack rates, vaccine availability and potency, health-service demand, case management and successive waves, with action timeframes and approximate budgets for selected responses.[18][11]
• Prepare laboratory equipment, safe biocontainment procedures, diagnostic reagents, staff training, alternative tests and rapid sample transport, including arrangements for difficult-to-identify viruses to be submitted to collaborating centres.[7][3]
• Prepare vaccine response arrangements early by developing candidate and seed strains, maintaining or accelerating potency-testing reagents, considering alternative manufacturing technologies, ensuring licensing and batch-release procedures, and consulting producers on emergency production, packaging and monthly supply.[21][22][23]
• Plan procurement, storage, transport and distribution of vaccines, antivirals, antibiotics, masks, syringes and needles, including emergency licensing, supply monitoring and safeguards against stolen or falsified products.[12][24]
• Promote equitable access through international consultation, pooled procurement or a clearing-house mechanism, humanitarian vaccine donations for designated high-risk groups where resources are lacking, and coordinated international purchasing and distribution.[13][24]
• Define national surveillance measures using timely data on occurrence, spread and impact, with potential indicators including clinical consultations, laboratory diagnoses, pneumonia admissions, mortality, and school or workplace absence.[11][20]
• Monitor global spread, transmission, disease impact, vaccine supply and utilisation, antiviral effectiveness and resistance, and vaccine adverse events through information-sharing among health authorities, laboratories, international partners, producers and the public.[10][24][14][25]
• Communicate rapidly and credibly through health authorities, professional bodies, media and electronic networks, coordinating information across sectors and countering misinformation, rumours and panic.[8][12][26]
• Review measures continuously through international and cross-sectoral expert consultation, assess pandemic impact after cessation, identify lessons, and update World Health Organization and national plans for future events.[15][3][27]

Monitoring & Evaluation

The framework combines World Health Organization (WHO)-led global risk assessment, pandemic-phase declarations and information sharing with national responsibility for surveillance, preparedness, response management and periodic reporting. It uses a staged approach from inter-pandemic detection of unusual human or animal influenza through confirmation of sustained transmission, pandemic spread, later waves and post-pandemic learning.[17][1][2][15][5]

• Maintain integrated human and animal influenza surveillance, with National Influenza Centres and laboratories investigating unusual infections, isolating and characterising viruses, reporting findings to WHO, and sending selected isolates to collaborating centres for comparison.[28][6][3][29]
• Assess new viruses through graduated preparedness levels, including confirmation of human infection, investigation of exposure and contacts, re-isolation and genetic sequencing, antiviral-sensitivity testing, and evaluation of evidence for sustained person-to-person transmission.[17][7][9][3]
• Define and disseminate case definitions, conduct special epidemiological investigations and serological prevalence studies, and encourage reporting of influenza-like disease clusters outside the normal influenza season.[19][10]
• Monitor spread and impact using data on clinical consultations, laboratory diagnoses, pneumonia admissions, mortality, school or workplace absence, hospital records, detailed case studies and population immunity.[15][20][30]
• Share global situation information with national health authorities, influenza centres and other participants through WHO communications, including FluNet, the Weekly Epidemiological Record, situation reports and policy guidance.[8][2][10][13]
• Track vaccine and medicine stocks, distribution, storage and use, and monitor vaccine-related adverse events, counterfeit or stolen products, antiviral effectiveness and antiviral resistance.[20][24][14][25]
• Require national authorities to report periodically to WHO on the progress of National Pandemic Planning Committees and to submit copies of national pandemic plans.[5]
• Review response measures continuously through international and national expert consultation, including assessment of laboratory and epidemiological evidence where human transmission cannot be excluded.[9][3]
• Evaluate total pandemic impact after the event, identify lessons, and use consultations and meetings to update the WHO influenza pandemic plan before returning to the inter-pandemic phase.[15]

Quantified performance targets, uniform reporting deadlines, a comprehensive evaluation methodology and a formal accountability framework are not specified in the supplied extracts, beyond WHO and national roles, laboratory reporting, committee progress reports, expert review and post-pandemic learning.[1][5][20][27][31]

Costing & Financing

The framework identifies substantial resource implications for surveillance, laboratory capacity, vaccines, antiviral medicines, emergency supplies, logistics, communication and health-service response, but does not provide a consolidated budget, monetary allocation, quantified funding gap or economic model.[6][12][26][3][32]

• Prepare approximate and indicative budgets for each selected national response, linked to defined action timeframes and decisions on exceptional control measures and financial support.[18][12]
• Estimate procurement, storage and transport costs for vaccines, antivirals, antibiotics, masks, syringes, needles and related emergency supplies.[12]
• Mobilise support for countries with limited capacity through WHO collaboration with the United Nations Children’s Fund, the International Red Cross and Red Crescent Movement, the World Bank and international aid agencies.[13][15]
• Consider pooled procurement, a central clearing house and humanitarian vaccine donations to improve equitable access for high-risk groups and countries unable to purchase vaccines.[24]
• Plan vaccine production and procurement around operational lead times, including at least six months to order eggs for conventional production and at least about eight months from identifying a new strain to initial vaccine availability.[32][21][22]
• Account for resource constraints affecting vaccine manufacturing, diagnostic reagents, laboratory training, sample transport, biocontainment, licensing, clinical trials and distribution capacity.[6][19][21][22]
• Recognise that the costs and supply constraints of antiviral medicines may make extensive prophylaxis unrealistic, while retaining supplies for critical groups such as health teams and laboratory workers.[14]
• Consider excess costs for enhanced surveillance, control measures and material procurement, as well as potential liabilities associated with vaccine reactions, disrupted pharmaceutical activity, quarantines, travel restrictions, cancelled events and school closures.[33][26]
• Redirect resources rapidly towards a credible new influenza threat and take unequal vaccine availability between richer and poorer countries into account during international consultation.[3][27]

Vaccination strategy should be determined early in light of available resources, because the intended scope of vaccination affects subsequent planning, procurement and delivery arrangements.[18]Vaccine costs may differ where governments provide vaccines free of charge rather than users purchasing them directly, and cost considerations should not displace public-health need in distribution decisions.[24]